X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CD40HVac, a therapeutic vaccine for HPV-associated malignancies, based on an innovative technology directly targeting dendritic cells (DC), which play a crucial role in the immune system by stimulating and regulating immune responses.
Lead Product(s): CD40HVac
Therapeutic Area: Oncology Product Name: CD40HVac
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gustave Roussy
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
The CD40.HIVRI.Env vaccine candidate is developed by the VRI that targets an immune response binding HIV envelope protein to monoclonal antibodies specifically targeting CD40 receptors on the surface of dendritic cells.
Lead Product(s): CD40.HIVRI.Env,Poly-ICLC
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
LinKinVax develops CD40HVac, a therapeutic vaccine for HPV-associated malignancies, based on an innovative technology directly targeting dendritic cells (DC), which play a crucial role in the immune system by stimulating and regulating immune responses.
Lead Product(s): CD40HVac
Therapeutic Area: Oncology Product Name: CD40HVac
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gustave Roussy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2023
Details:
LinKinVax has huge capabilities to accelerate the clinical development of its innovative protein-based vaccine platform, which can be tuned to develop therapeutic and prophylactic vaccines, adapt to new or fast mutating pathogens and enhance first generation vaccine.
Lead Product(s): Protein-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Andre-Jacques Auberton-Herve
Deal Size: $7.9 million Upfront Cash: Undisclosed
Deal Type: Financing January 09, 2023
Details:
The agreement with GTP relates to the development of Covid-19 Anti-CD40.COV2 vaccine, from development of the cell line to production of a clinical batch to be tested in a clinical trial. LinKinVax’s technology is based on a monoclonal antibody that targets dentritic cells.
Lead Product(s): Covid-19 Anti-CD40.COV2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Covid-19 Anti-CD40.COV2
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: GTP Bioways
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
